SCHEMBL9974708

SCHEMBL9974708

COC(=O)c1ccc(C)c(-c2ccc3c(=O)[nH]cc(C)c3c2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 2/20 0.47
PARP1 P09874 3/20 0.44
GRIK1 P39086 1/20 0.43
GRIA1 P42261 1/20 0.43
GRIA2 P42262 1/20 0.43
GRIA3 P42263 1/20 0.43
GRIA4 P48058 1/20 0.43
ASH1L Q9NR48 1/20 0.42
PDGFRB P09619 1/20 0.41
MAPK1 P28482 1/20 0.41
AXL P30530 1/20 0.41
SGK1 O00141 1/20 0.41
CAMKK2 Q96RR4 1/20 0.41
CSNK2A1 P68400 1/20 0.40
NPC1 O15118 1/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
DYRK1A Q13627 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2420478 0.86 GRIK1 (0.59) MAPK14PARP1GRIK1GRIA1GRIA2
SCHEMBL2419992 0.82 MAPK14 (0.56) MAPK14PARP1GRIK1GRIA1GRIA2
SCHEMBL9974684 0.77 KDM4E (0.47) MAPK14PARP1GRIK1GRIA1GRIA2
SCHEMBL30283537 0.75 PARP1 (0.49) MAPK14PARP1ASH1LPDGFRBAXL
SCHEMBL18190480 0.73 GRIA1 (0.62) PARP1GRIK1GRIA1GRIA2GRIA3
SCHEMBL2342676 0.73 PTGS2 (0.51) MAPK14GRIK1GRIA1GRIA2GRIA3
SCHEMBL1553838 0.73 NPC1 (0.63) PARP1ASH1LCSNK2A1NPC1KDM4E
SCHEMBL30159619 0.73 NPC1 (0.63) PARP1ASH1LCSNK2A1NPC1KDM4E
SCHEMBL18152355 0.72 ERN1 (0.49) MAPK14GRIK1GRIA1GRIA2GRIA3
SCHEMBL4765793 0.72 MAPT (0.49) MAPK14PDGFRBMAPK1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2144881-B1 ISOQUINOLINONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE ( COPD ) AND ASTHMA ASTRAZENECA AB (SE) 2012-06-20 EP disclosed
US-8012979-B2 Compounds and their uses 707 ASTRAZENECA AB (SE) 2011-09-06 US disclosed
US-8012979-B2 Compounds and their uses 707 ASTRAZENECA AB (SE) 2011-09-06 US disclosed
US-20090023746-A1 COMPOUNDS AND THEIR USES 707 ASTRAZENECA AB (SE) 2009-01-22 US disclosed
US-20090023746-A1 COMPOUNDS AND THEIR USES 707 ASTRAZENECA AB (SE) 2009-01-22 US disclosed
WO-2008122765-A1 NEW COMPOUNDS AND THEIR USES 707 ASTRAZENECA AB (SE) 2008-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023746-A1 COMPOUNDS AND THEIR USES 707 CYP3A7, UGT1A7, UGT2B7 MAPK14 4537/4885PARP1 209/4885GRIK1 2534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.